Increasing options for the treatment of osteoporosis

From the Endocrine Research Unit, College of Medicine, Mayo Clinic, Rochester, MN.This article (10.1056/NEJMe0905480) was published on August 11, 2009, at
New England Journal of Medicine (Impact Factor: 54.42). 09/2009; 361(8):818-20. DOI: 10.1056/NEJMe0905480
Source: PubMed
    • "In 2009, the Food and Drug Administration has approved the annual injection of zoledronic acid for the prevention of osteoporosis in menopausal populations (Khosla 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the 3-year clinical and radiographic data of fixed implant-supported dental prosthesis delivered to patients having taken alendronate 35–70 mg weekly for at least 3 years before implant placement. Materials and Methods: Forty consecutive patients treated with oral bisphosphonates and requiring an implant-supported restoration were recruited in two private centers between January 2008 and December 2011. Implants were inserted through minimally invasive approach under antibacterial and antibiotic treatment, 6 months after alendronate administration stopping. After 4 months of submerged healing, implants underwent prosthetic loading. Hygiene maintenance and clinical assessments were scheduled every 4 months for 3 years. Outcome measures were the following: implant and prosthetic success, survival rates, any observed clinical complications, marginal bone remodeling, probing pocket depth and bleeding-on-probing. Results: At the end of the study, eight patients dropped out. The final sample size resulted in 32 consecutive partially or fully edentulous patients (32 females; mean age 64.6 years) with 98 submerged implants. In only one patient, maxillary implant failed during healing period. No prosthesis failed during the entire follow-up, and no major complications were recorded. Implant and prostheses success resulted in an overall survival rate of 98, 98% and 100%, respectively. Three-year mean marginal bone loss was 1.35 � 0.21 (CI 95% 1.24–1.38). Successful soft tissue parameters were found around all implants. Conclusions: Oral bisphosphonate therapy did not appear to significantly affect implant survival and success in case of accurate treatment time selection, minimally invasive surgical approach and constant follow-up. Further prospective studies involving larger sample sizes and longer durations of follow-up are required to confirm these results.
    Clinical Oral Implants Research 07/2015; DOI:10.1111/clr.12662 · 3.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background/Introduction: Osteoporosis results in a significant increase in fractures, leading to morbidity and mortality. Adherence is a concern with commonly used antiresorptive agents, the bisphosphonates. Denosumab, which inhibits bone resorption by a different mechanism and is administered subcutaneously every 6 months, may provide an advantage in decreasing fracture risk in those with osteoporosis.
    Canadian Pharmacists Journal 03/2011; 144(2):72-78. DOI:10.3821/1913-701X-144.2.72
  • [Show abstract] [Hide abstract]
    ABSTRACT: The management of Bartholin cysts by inserting a silver nitrate stick into the cyst cavity was performed in 15 patients. The cyst wall was expelled in 14 (93%) with no recurrence in a year. The only complication was the cauterization of the surrounding mucosa (20%). This technique seems to offer benefit over conventional treatment modalities.
    European Journal of Obstetrics & Gynecology and Reproductive Biology 03/1999; 82(2):231-2. DOI:10.1016/S0301-2115(98)00229-2 · 1.63 Impact Factor
Show more